SCIO Scios Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc.

SCIO 0.01000

0.0%

Aug 19 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Rick Strange who started this subject	2/27/2002 4:22:44 PM
From: nigel bates	Read Replies (2) of 1477

Scios Announces Start of Phase II Clinical Trials of New Oral Treatment For Rheumatoid Arthritis SUNNYVALE, Calif., Feb. 27 /PRNewswire-FirstCall/ -- Scios Inc. (Nasdaq: SCIO - news) announced today that enrollment has begun in a Phase IIa clinical trial evaluating SCIO-469, its novel oral p38 kinase inhibitor for the treatment of rheumatoid arthritis (RA). ``This marks a major milestone for the company as we advance another promising compound from our pipeline into further clinical development,'' said Darlene P. Horton, M.D., Scios' Vice President of Medical Affairs. ``SCIO-469 could become a valuable new oral treatment for the millions of RA patients affected by this disease worldwide.'' This multi-center, randomized, placebo-controlled clinical study will enroll 120 patients who have active RA and are receiving methotrexate. The main objective of the study is to evaluate the safety and tolerability of six escalating doses of SCIO-469 in RA patients. The company expects to announce results from this study in the first quarter of 2003...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next